Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Outcome
100%
Prognostic Factors
100%
T-cell Lymphoma
100%
International Prognostic Index
100%
B-line Score
100%
Multi-institutional Study
100%
T-cell non-Hodgkin Lymphoma
80%
Lymphoma Patients
60%
Doxorubicin
40%
Median Overall Survival
20%
Overall Response Rate
20%
Neutropenia
20%
Progression-free Survival
20%
Overall Survival
20%
Poor Outcome
20%
Bone Marrow Involvement
20%
Epirubicin
20%
Prognostic Groups
20%
Cyclophosphamide
20%
Prognostic Model
20%
Bleomycin
20%
Long-term Survival
20%
B Symptoms
20%
Prednisone
20%
Median Progression-free Survival
20%
Bulky Disease
20%
Medicine and Dentistry
T-Cell Lymphoma
100%
Prognostic Factor
100%
International Prognostic Index
100%
Treatment Outcome
100%
Non-Hodgkin Lymphoma
80%
T Cell
80%
Overall Survival
40%
Progression Free Survival
40%
Doxorubicin
40%
Prospective Study
20%
Epirubicin
20%
Neutropenia
20%
Bleomycin
20%
Long Term Survival
20%
B Symptoms
20%
CHOP
20%
Cyclophosphamide
20%
Vincristine
20%
Prednisone
20%
Diseases
20%
Prognostic Model
20%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
T Cell Lymphoma
100%
Progression Free Survival
50%
Overall Survival
50%
Doxorubicin
50%
Prospective Study
25%
Neutropenia
25%
Epirubicin
25%
Cyclophosphamide
25%
Long Term Survival
25%
Vincristine
25%
Prednisone
25%
Bleomycin
25%
Diseases
25%
Immunology and Microbiology
T Cell
100%
Overall Survival
40%
Progression Free Survival
40%
Cyclophosphamide
20%
Long Term Survival
20%
Prednisone
20%
Prognostic Model
20%